公开(公告)号：US07772366B2

公开(公告)日：2010-08-10

申请号：US11901843

申请日：2007-09-18

申请人： Guy W. Bemis ,  Julian M. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

发明人： Guy W. Bemis ,  Julian M. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

IPC分类号： C07K38/07

CPC分类号： C07D243/08 ,  A61K38/00 ,  C07D243/12 ,  C07D263/56 ,  C07D413/04 ,  C07D487/04 ,  C07K5/0202 ,  C07K5/06052 ,  C07K5/0812

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

摘要翻译： 本发明涉及作为白介素-1和bgr的抑制剂的新型化合物。 转化酶。 本发明的ICE抑制剂的特征在于具体的结构和物理化学特征。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗白介素-1介导的疾病（包括炎性疾病，自身免疫性疾病和神经变性疾病）的药物。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性的方法和用于治疗白细胞介素-1介导的疾病的方法。